Plasmid Construct Decision

TargetAMD consortium took the decision of the final gene delivery plasmid construct. The PEDF encoding transposon and the Sleeping Beauty 100X encoding transposase will be used as DNA sequence and will be safety enhanced by applying the pFAR technology. This technology increases safety by eliminating the antibiotic resistance backbone from the plasmids. Additionally, reduced size of the resulting pFAR miniplasmids will provoke better gene integration moments into the target cells. The pFAR plasmids were developed by partner CNRS and extensively tested in vitro by partner UKA, UNIGE and UD-G.

30. January 2014
Categories: Target AMD